GE HealthCare Financial Model
Medical Devices Company Financials Example (Free Excel Download)
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator that provides integrated equipment, services, and data analytics to hospitals and clinicians.
professionals from Deloitte
Used by professionals from
About this model
This model provides a comprehensive equity valuation and scenario planning tool for GE HealthCare Technologies Inc. (GEHC), enabling an analyst to forecast the company's margin expansion trajectory, backlog conversion, and free cash flow generation following its spin-off from General Electric and recent strategic M&A (e.g., Intelerad).
- What the company does: GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator that provides integrated equipment, services, and data analytics to hospitals and clinicians.
- Business segments:
- Imaging (~53% of revenue)
- Ultrasound (~17% of revenue)
- Patient Care Solutions (PCS) (~15% of revenue)
- Pharmaceutical Diagnostics (PDx) (~15% of revenue)
- Key geographies: United States (~45%), EMEA (~25%), China (~15%), Rest of World (~15%).
- Business model type: Hybrid capital equipment and recurring revenue (razor/razorblade model in PDx, plus high-margin multi-year service contracts and software/AI add-ons for Imaging/Ultrasound).
- Competitive position: Top-tier global oligopoly player alongside Siemens Healthineers and Royal Philips in imaging and ultrasound; market leader in contrast media.
- Recent major events: Spun off from General Electric in January 2023; announced the $2.3 billion acquisition of Intelerad (cloud-enabled enterprise imaging) in late 2025; navigated significant supply chain and tariff headwinds (Section 122) throughout 2024-2025.
The downloadable GE HealthCare financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsGE HealthCare financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $17.59B | $18.34B | $19.55B | $19.67B | $20.63B |
| Gross profit | $7.17B | $7.18B | $7.92B | $8.21B | $8.25B |
| Operating income | $2.79B | $2.52B | $2.44B | $2.63B | $2.76B |
| Net income | $2.25B | $1.92B | $1.57B | $1.99B | $2.08B |
How to build a detailed financial model for GE HealthCare
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Imaging
- Segment name: Imaging (includes CT, MR, Molecular Imaging, X-ray, and Women's Health).
- Revenue driver formula: (Installed Base x Replacement Rate x Average Selling Price) + (Installed Base x Service Contract Attach Rate x Annual Service Fee).
- Historical growth rate: 3-5% organic CAGR.
- Key growth levers and headwinds: Driven by hospital capital expenditure cycles, AI-enabled software upgrades (e.g., AIR Recon DL), and aging population demographics. Headwinds include China market softness and anti-corruption campaigns delaying tenders.
- Pricing dynamics: Highly competitive, tender-based pricing for equipment; high-margin, sticky pricing for long-term service agreements.
- Revenue recognition notes: Equipment recognized at point of delivery/installation; service revenue recognized ratably over the contract term.
- Seasonality: Q4 is historically the strongest quarter (often >28% of annual revenue) due to hospital year-end budget flushes.
Ultrasound
- Segment name: Ultrasound (consoles, handheld devices, and intraoperative imaging).
- Revenue driver formula: Volume of Units Sold x Average Selling Price (ASP) + Software/Service Revenue.
- Historical growth rate: 2-4% organic CAGR.
- Key growth levers and headwinds: Shift towards point-of-care and handheld devices (Vscan); integration of AI for automated measurements.
- Pricing dynamics: Spot purchases and fleet replacements; lower ASP than heavy imaging but higher volume.
- Revenue recognition notes: Primarily upfront upon delivery.
- Seasonality: Moderate Q4 skew, but more evenly distributed than heavy Imaging.
Patient Care Solutions (PCS)
- Segment name: Patient Care Solutions (monitoring, anesthesia delivery, ECG, maternal infant care).
- Revenue driver formula: Hospital Bed Expansion/Upgrades x Equipment ASP + Consumables Volume.
- Historical growth rate: 1-3% organic CAGR.
- Key growth levers and headwinds: Post-COVID normalization of monitoring equipment demand; growth driven by wireless/wearable monitoring and enterprise software integration.
- Pricing dynamics: Contractual and competitive.
- Revenue recognition notes: Mix of upfront equipment and recurring consumables/software.
- Seasonality: Standard hospital purchasing seasonality (Q4 peak).
Pharmaceutical Diagnostics (PDx)
- Segment name: Pharmaceutical Diagnostics (contrast media and molecular imaging agents/radiopharmaceuticals).
- Revenue driver formula: Procedure Volumes (CT/MR scans) x Dose Price.
- Historical growth rate: 8-12% organic CAGR (fastest-growing segment).
- Key growth levers and headwinds: Driven by global imaging procedure volumes and new radiopharmaceutical introductions (e.g., Flyrcado). Headwinds include generic competition for older contrast agents.
- Pricing dynamics: Regulated and contractual; tight global supply has supported pricing power recently.
- Revenue recognition notes: Recognized upon shipment/delivery of consumables.
- Seasonality: Relatively stable throughout the year, tracking elective procedure volumes.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: Raw materials (metals, resins, rare earths for magnets), direct manufacturing labour, logistics/freight, and tariffs.
- Gross margin range: 39% - 41%.
- Key input costs and commodity exposures: Helium (for MRIs), electronics/semiconductors, logistics costs (oil-linked), and significant exposure to US-China tariffs.
- How COGS scales with revenue: Step-function for manufacturing capacity; service revenue carries significantly higher gross margins (~60%+) than equipment sales (~30%+), driving margin expansion as the installed base ages.
Operating Expenses
- R&D: ~6.0% - 6.5% of revenue. Covers hardware engineering, AI/machine learning algorithms, and clinical validation.
- SG&A: ~19.0% - 21.0% of revenue. Includes large direct sales forces, field service engineers, and corporate overhead (which increased post-spin-off).
- Depreciation & Amortisation: ~3.5% - 4.5% of revenue, heavily weighted towards amortisation of acquired intangibles.
- Stock-Based Compensation: ~0.8% - 1.2% of revenue.
- Restructuring / one-time charges: Frequent "optimization" and spin-off related separation costs in 2023-2025, transitioning to standard lean productivity initiatives ("Heartbeat" business system).
Margin Profile
- Gross margin: 39.0% - 41.0%.
- EBITDA margin: 17.0% - 19.0%.
- Operating margin (Adjusted EBIT): 15.0% - 16.7% (management target is continuous expansion).
- Net margin: 9.5% - 10.5%.
- Margin trend: Expanding. Driven by price increases, "Heartbeat" lean productivity, and a mix-shift towards PDx and software, partially offset by severe tariff headwinds in 2024/2025.
Balance Sheet Structure
- Total assets: ~$32.0 - $33.0 billion.
- Key asset categories: High proportion of Goodwill and Intangible Assets (~$15.0B+) from legacy GE acquisitions and recent M&A; Inventory (~$3.0B); Receivables (~$4.5B).
- Goodwill & intangibles as % of total assets: ~45-50%.
- Working capital profile:
- Days Sales Outstanding (DSO): 75 - 85 days.
- Days Inventory Outstanding (DIO): 90 - 105 days (complex manufacturing supply chain).
- Days Payable Outstanding (DPO): 80 - 95 days.
- Net working capital as % of revenue: ~10% - 15%.
- Is working capital positive or negative?: Positive. The company consumes cash for inventory builds to support its massive $21.8B backlog.
- PP&E: ~$2.0 - $2.5 billion. Consists of global manufacturing facilities (e.g., MRI magnet factories).
- Right-of-use assets / operating leases: ~$400 - $500 million (immaterial relative to total assets).
Capital Expenditure & Investment
- Capex as % of revenue: 2.0% - 2.5% (~$400M - $500M annually).
- Maintenance capex vs. growth capex: ~60% maintenance / 40% growth (capacity expansion for PDx and new product tooling).
- Major capex programmes underway or planned: Expanding contrast media manufacturing capacity to meet tight global supply.
- Capitalised software / development costs: Material, representing internal use and commercial software development for AI/digital platforms.
- M&A pattern: Bolt-on to medium-sized transformational. Acquired BK Medical (pre-spin), MIM Software, Nihon Medi-Physics, icometrix, and announced Intelerad ($2.3B).
- Typical acquisition multiple paid: 4x - 6x EV/Revenue for high-margin software/AI assets.
Debt & Capital Structure
- Total debt: ~$10.0 billion (issued at spin-off).
- Net debt: ~$5.5 billion (Total debt of $10.0B less ~$4.5B cash).
- Debt/EBITDA ratio: ~1.5x - 2.0x (Targeting investment-grade profile).
- Credit rating: Investment Grade (Baa2/BBB).
- Key debt instruments: Senior unsecured notes across various maturities (3-year to 30-year tranches issued in late 2022/early 2023) and a $3.5B revolving credit facility.
- Maturity profile: Well-laddered, with initial maturities beginning in 2025/2026.
- Interest rate profile: Predominantly fixed-rate bonds; weighted average cost of debt ~4.5% - 5.0%.
- Covenants: Standard investment-grade covenants (interest coverage, leverage maximums).
- Share repurchase programme: Active. $1.0 billion authorization (repurchased ~$200M in 2025).
- Dividend policy: $0.14 per share annually ($0.035 quarterly), representing a very low payout ratio (~3%) and yield (~0.2%), prioritizing M&A and debt paydown.
Cash Flow Characteristics
- Operating cash flow conversion: ~0.9x - 1.1x OCF / Net Income (~$2.0B OCF).
- Free cash flow margin: 7.0% - 8.5% (FCF / Revenue).
- Major non-cash items that bridge net income to OCF: Depreciation & Amortisation (~$800M), Stock-Based Compensation, and deferred taxes.
- Working capital cash flow impact: Inventory builds for backlog execution have been a use of cash; supply chain normalization is expected to release working capital.
- Capex intensity: Low (asset-light relative to legacy GE industrial businesses).
- Cash tax rate vs. GAAP effective tax rate: Adjusted ETR is typically 20% - 21%. Cash taxes generally align with GAAP taxes post-spin.
Sheet Structure
- Assumptions: Hardcoded drivers for macroeconomic inputs, segment growth, margins, tariffs, and capital allocation.
- Revenue Build: Segment-level build for Imaging, Ultrasound, PCS, and PDx, including volume/price assumptions and backlog conversion.
- Income Statement: Consolidated P&L mirroring the 10-K, down to Net Income Attributable to GE HealthCare.
- Balance Sheet: Standard assets, liabilities, and equity. Must break out Goodwill/Intangibles and specific working capital lines.
- Cash Flow Statement: Indirect method starting from Net Income, adjusting for D&A, working capital changes, capex, M&A, and financing activities.
- Debt Schedule: Tranche-by-tranche debt build, interest expense calculation, and mandatory repayments.
- Working Capital Schedule: DSO, DIO, DPO calculations driving the balance sheet and cash flow.
- Depreciation & Amortisation: Waterfall for existing PP&E/Intangibles and new capex/M&A additions.
- DCF Valuation: Unlevered free cash flow build, WACC calculation, terminal value, and implied share price.
- Outputs & Dashboard: Summary of key metrics (Adjusted EBIT margin, FCF conversion, EPS, leverage).
Key Financial Relationships
- Imaging Revenue = Prior Year Imaging Revenue x (1 + Imaging Organic Growth Rate) + M&A Contribution.
- PDx Revenue = Prior Year PDx Revenue x (1 + Procedure Volume Growth + Price/Mix Impact).
- Total Revenue = Imaging Revenue + Ultrasound Revenue + PCS Revenue + PDx Revenue.
- Gross Profit = Total Revenue - (Total Revenue x Blended COGS % + Tariff Impact).
- Adjusted EBIT = Gross Profit - R&D Expense - SG&A Expense (excluding one-time spin-off/restructuring costs).
- Adjusted EBIT Margin = Adjusted EBIT / Total Revenue (Targeting ~15.8% - 16.1% in near-term).
- Interest Expense = (Beginning Total Debt + Ending Total Debt) / 2 x Weighted Average Interest Rate.
- Tax Expense = EBT x Adjusted Effective Tax Rate (20% - 21%).
- Free Cash Flow = Cash Flow from Operations - Capital Expenditures.
- Free Cash Flow Conversion = Free Cash Flow / Adjusted Net Income (Targeting >70%).
- Ending Backlog = Beginning Backlog + Orders (Book-to-Bill x Revenue) - Revenue Recognized.
- Diluted EPS = Adjusted Net Income / Diluted Shares Outstanding.
Cross-Sheet Dependencies
- Assumptions feeds all other sheets (Revenue Build, P&L, Balance Sheet drivers).
- Revenue Build feeds the top line of the Income Statement and drives the Working Capital Schedule (Receivables, Payables).
- Working Capital Schedule feeds the Balance Sheet (Current Assets/Liabilities) and the Cash Flow Statement (Change in NWC).
- Debt Schedule feeds Interest Expense on the Income Statement and Debt balances on the Balance Sheet. *Circularity risk*: Interest expense lowers Net Income, which lowers Cash, which could trigger revolver paydown/draw, which changes Interest Expense. Use a circularity toggle.
- Depreciation & Amortisation feeds the Income Statement (Operating Expenses) and the Cash Flow Statement (Non-cash add-back), as well as PP&E/Intangible balances on the Balance Sheet.
- Cash Flow Statement ending cash feeds the Balance Sheet cash line item.
Sign Convention
- Revenue and Assets: Positive.
- Expenses and Liabilities: Positive on their specific schedules, but subtracted in aggregation formulas (e.g., Gross Profit = Revenue - COGS).
- Cash Flow: Inflows are positive, outflows (Capex, Dividends, Debt Repayment) are negative.
- Contra-accounts: Accumulated Depreciation is negative on the Balance Sheet.
Things Most Likely to Go Wrong
- Tariff Impacts: GEHC has massive exposure to US-China tariffs (e.g., Section 122). The model must include a specific line item or COGS adjustment for tariffs (~$245M in recent years) to accurately bridge GAAP to Adjusted EBIT.
- Standalone vs. Carve-out Financials: Historical data prior to 2023 includes GE corporate allocations that do not reflect the current standalone cost structure. Do not straight-line pre-2023 SG&A margins.
- Backlog Conversion: GEHC has a massive $21.8B backlog. Assuming a standard historical revenue growth rate without factoring in the timing of backlog conversion (which is constrained by supply chain, not demand) will misstate near-term revenue.
- M&A Pro-Forma Adjustments: The $2.3B Intelerad acquisition will add significant intangible amortisation and alter the AVS/Imaging software mix. The model must account for this half-year impact in 2026.
- China Market Softness: China represents ~15% of sales. Anti-corruption campaigns have delayed tenders. Applying a blanket global growth rate will overstate near-term growth; China must be modeled conservatively.
- Free Cash Flow Definition: GEHC defines FCF as Operating Cash Flow less Capex. Ensure the model does not accidentally deduct capitalized software twice if it's already in Capex.
- Pension Liabilities: As a former GE subsidiary, GEHC inherited some pension obligations. Ensure these are captured in long-term liabilities and non-operating expenses.
- Adjusted vs. GAAP EPS: Management guides to Adjusted EPS (excluding amortisation of acquired intangibles and restructuring). The model must clearly bridge GAAP Net Income to Adjusted Net Income to compare against consensus.
Validation Checks
- Adjusted EBIT Margin: Should be in the 15.3% - 16.7% range. Flag if it expands beyond 18% without a massive shift in software mix.
- Free Cash Flow Conversion: FCF / Adjusted Net Income should be >70%.
- Book-to-Bill Ratio: Should remain >1.0x (historically ~1.06x - 1.07x). If <1.0x, backlog is shrinking.
- Effective Tax Rate: Should remain tightly bound between 20.0% and 21.0% per management guidance.
- Capex / Revenue: Should be strictly between 2.0% and 3.0%.
- Debt / EBITDA: Should remain below 2.5x to maintain the investment-grade rating.
- Balance Sheet Check: Total Assets must exactly equal Total Liabilities + Shareholders' Equity.
- Dividend Payout: Should be immaterial (~$0.14 per share / ~$4.50 EPS = ~3% payout ratio).
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Imaging Organic Growth | 4.0 | % | Blended average of recent performance and backlog conversion |
| Ultrasound Organic Growth | 2.5 | % | Normalized post-COVID demand |
| PCS Organic Growth | 1.5 | % | Stable replacement cycle |
| PDx Organic Growth | 10.0 | % | Strong pricing power and procedure volume growth |
| Blended Gross Margin | 40.5 | % | Historical average, adjusting for tariff mitigation |
| R&D as % of Revenue | 6.2 | % | Consistent with management's innovation investment targets |
| SG&A as % of Revenue | 19.5 | % | Reflects lean productivity ("Heartbeat") improvements |
| Tariff Expense Impact | 200 | $M | Estimated ongoing headwind, mitigating from 2025 peak |
| DSO (Days Sales Outstanding) | 80 | Days | Historical average based on receivables |
| DIO (Days Inventory Outstanding) | 98 | Days | Elevated due to supply chain buffering |
| DPO (Days Payable Outstanding) | 88 | Days | Historical average |
| Capex as % of Revenue | 2.3 | % | Management guidance (~$480M on ~$20.6B revenue) |
| Effective Tax Rate | 20.5 | % | Midpoint of 20% - 21% management guidance |
| Weighted Avg. Interest Rate | 4.8 | % | Based on current debt stack issued at spin-off |
| Share Repurchases | 250 | $M/yr | Run-rate based on $1B authorization |
| Annual Dividend per Share | 0.14 | $ | Current declared policy ($0.035 quarterly) |
| WACC | 8.5 | % | Standard for large-cap MedTech |
| Terminal Growth Rate | 2.5 | % | Long-term GDP + healthcare demographic tailwinds |
Data Sources & Benchmarks
- Filings: SEC EDGAR (GEHC 10-K, 10-Q, 8-K), GE HealthCare Investor Relations website.
- Key Peers for Benchmarking: Siemens Healthineers (SHL.DE), Royal Philips (PHIA.AS), Hologic (HOLX), Canon Medical Systems.
- Industry Data Sources: Evaluate procedure volumes via IQVIA, Medicare utilization data, and American College of Radiology (ACR) reports.
- Consensus Estimates: FactSet, Bloomberg, or Quartr for consensus revenue and Adjusted EPS.
Sources
- GE HealthCare Q4 and Full Year 2025 Earnings Release and Presentation (February 2026)
- GE HealthCare 2024 Annual Report on Form 10-K
- GE HealthCare Investor Day Presentations (November 2024)
- General Electric Company Form 10-K (Historical spin-off context)
- AlphaSpread and TradingView GEHC Financial Summaries
Do more with the GE HealthCare model
Frequently asked
What does GE HealthCare do?+
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator. It provides integrated equipment, services, and data analytics to hospitals and clinicians worldwide.
How does GE HealthCare generate revenue?+
GE HealthCare employs a hybrid business model that combines capital equipment sales with recurring revenue streams. This includes a razor/razorblade model in Pharmaceutical Diagnostics, along with high-margin multi-year service contracts and software/AI add-ons for its Imaging and Ultrasound segments.
What are GE HealthCare's main business segments?+
GE HealthCare's primary business segments are Imaging, which contributes approximately 53% of revenue, and Ultrasound, accounting for about 17%. Patient Care Solutions and Pharmaceutical Diagnostics each represent roughly 15% of the company's revenue.
What is GE HealthCare's capital expenditure strategy?+
GE HealthCare's capital expenditure typically ranges from 2.0% to 2.5% of revenue annually, equating to approximately $400M - $500M. About 60% of this is for maintenance, while 40% is allocated to growth initiatives such as expanding contrast media manufacturing capacity and new product tooling.
What are the key balance sheet characteristics of GE HealthCare?+
GE HealthCare's balance sheet is characterized by a high proportion of Goodwill and Intangible Assets, making up approximately 45-50% of its total assets. The company also maintains a positive net working capital profile, consuming cash for inventory builds to support its substantial $21.8 billion backlog.
Can I download an Excel financial model for GE HealthCare?+
No, an Excel financial model for GE HealthCare is not currently available for download. The provided model serves as a comprehensive equity valuation and scenario planning tool for analysts to forecast the company's financial performance.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Medical Devices Company Financial Models
Browse another company in the same sector.
Abbott Laboratories
Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad line of healthcare products.
Align Technology
Align Technology is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry.
Baxter International
Baxter International Inc.
Becton Dickinson
Becton, Dickinson and Company (BD) is a leading global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products.
Boston Scientific
Boston Scientific is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties.
Cooper Companies
The Cooper Companies, Inc.
Dexcom
Dexcom is a medical device company focused on the design, development, and commercialisation of continuous glucose monitoring systems that provide real-time glucose readings for people with diabetes, replacing traditional fingerstick testing.
Edwards Lifesciences
Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease.
Explore more Healthcare financial model templates.
